Wearable heart monitor moves from lab to clinical trial
A new lightweight, gel-free and waterproof heart monitor that provides real-time insights into heart health is being trialed at an Australian clinic. Originally invented through research at RMIT University and now being developed by Australian startup Lubdub, the wearable wireless patch continuously tracks the heart's rhythm for up to 14 days—giving doctors the same detailed information as a…
A new lightweight, gel-free, waterproof heart monitor designed for continuous heart rhythm tracking is moving from the laboratory to clinical trials in Australia. This wearable wireless patch, developed by Australian startup Lubdub, is capable of monitoring heart rhythm for up to 14 days, providing doctors with a level of detail typically only available through a medical-grade electrocardiogram (ECG) Holter monitor.
The prototype is being tested at Midlands Medical Specialists in Perth, Western Australia, as part of a clinical trial.
Unlike traditional Holter monitors, the ECG patch is more comfortable to wear and produces cleaner data, as the flexible sensors make better contact with the skin. In earlier testing involving healthy volunteers, the patch demonstrated promising results, with data being 18 times cleaner compared to traditional Holter monitors.
The technology's potential to reduce the effort required to generate cardiac reports could allow the same workforce to monitor up to 85% more patients before the implementation of other enabling tools like AI. This could help reduce delays between symptoms and treatment, improving access to cardiac monitoring in both metropolitan and rural, remote areas of Australia.
Cardiovascular disease is a major global health issue, responsible for a third of all deaths worldwide, and nearly a quarter in Australia. Despite its high prevalence, early symptoms are often missed, with most heart failure diagnoses and hospital admissions occurring unexpectedly in emergency situations. The innovation aims to provide simpler and more effective screening, with the ultimate goal of combining wearable ECG monitoring, noninvasive cardiac biomarker testing, and wearable ultrasound imaging into a single platform.
Lubdub aims to bring together these three technologies in a single software platform, making heart testing more accessible, particularly in regions with limited infrastructure and shortages of specialists. The Heart Foundation has recognized Lubdub as one of its 10 most promising heart health projects for 2026.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.